

UC Davis

UC Davis Previously Published Works

Title

Predictive models for identifying risk of readmission after index hospitalization for hip arthroplasty: A systematic review.

Permalink

<https://escholarship.org/uc/item/34656338>

Authors

Mahajan, Satish

Mahajan, Amey

Nguyen, Chantal

et al.


Publication Date

2020

DOI

10.1016/j.jor.2020.03.045

Peer reviewed



Predictive models for identifying risk of readmission after index hospitalization for hip arthroplasty: A systematic review

Satish M. Mahajan^{a,*}, Amey Mahajan^b, Chantal Nguyen^c, Justin Bui^d, Bruce T. Abbott^e, Thomas F. Osborne^f

^a Veterans Affairs Palo Alto Health Care System, Building 100, Office C3-125, 3801 Miranda Ave, Palo Alto, CA, 94304, USA

^b C2OPS, Inc., 22031 Rae Ln, Cupertino, CA, 95014, USA

^c George Washington University School of Medicine and Health Sciences, 2300 I Street NW, Washington D.C., 20052, USA

^d Lake Erie College of Osteopathic Medicine at Bradenton, 5000 Lakewood Ranch Boulevard, Bradenton, FL, 34211, USA

^e University of California, Davis, Blaisdell Medical Library, 4610 X St, Sacramento, CA, 95817, USA

^f Veterans Affairs Palo Alto Health Care System, Building 101, Office C2-139, 3801 Miranda Ave, Palo Alto, CA, 94304, USA

ARTICLE INFO

Keywords:

Total hip arthroplasty
Hip replacement
Patient readmission
Risk factors
Statistical models

ABSTRACT

Background: An aging United States population profoundly impacts healthcare from both a medical and financial standpoint, especially with an increase in related procedures such as Total Hip Arthroplasty (THA). The Hospital Readmission Reduction Program and Comprehensive Care for Joint Replacement Program incentivize hospitals to decrease post-operative readmissions by correlating reimbursements with smoother care transitions, thereby decreasing hospital burden and improving quantifiable patient outcomes. Many studies have proposed predictive models built upon risk factors for predicting 30-day THA readmissions.

Questions: (1) Are there validated statistical models that predict 30-day readmissions for THA patients when appraised with a standards-based, reliable assessment tool? (2) Which evidence-based factors are significant and have support across models for predicting risk of 30-day readmissions post-THA?

Methods: Five major electronic databases were searched to identify studies that examined correlations between post-THA readmission and risk factors using multivariate models. We rigorously applied the PRISMA methodology and TRIPOD criteria for assessment of the prognostic studies.

Results: We found 26 studies that offered predictive models, of which two presented models tested with validation cohorts. In addition to the many factors grouped into demographic, administrative, and clinical categories, bleeding disorder, higher ASA status, discharge disposition, and functional status appeared to have broad and significant support across the studies.

Conclusions: Reporting of recent predictive models establishing risk factors for 30-day THA readmissions against the current standard could be improved. Aside from building better performing models, more work is needed to follow the thorough process of undergoing calibration, external validation, and integration with existing EHR systems for pursuing their use in clinical settings. There are several risk factors that are significant in multiple models; these factors should be closely examined clinically and leveraged in future risk modeling efforts.

1. Introduction

1.1. Background

According to the United States Census Bureau's 2017 National Population Projections, the year 2030 marks a demographic milestone by which one in five citizens will be greater than 65 years old.^{1,2} With this aging population comes a skewed burden on the healthcare system,

which is tasked with addressing a dramatic increase in procedures such as primary joint replacements. The most common primary joint replacements are Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA).³ In particular, THA is one of the quickest growing procedures in the U.S., with a projected 520,000 arthroplasties per year by 2030, entailing a 174% increase.^{4,5} The exponential growth in the number of procedures invites a greater potential for post-surgical complications, such as surgical site infections, sepsis, joint dislocations,

* Corresponding author.

E-mail addresses: satish.mahajan@va.gov (S.M. Mahajan), amey@c2ops.io (A. Mahajan), nguyenct@gwmail.gwu.edu (C. Nguyen), jbui46890@med.lecom.edu (J. Bui), btabbott@ucdavis.edu (B.T. Abbott), thomas.osborne@va.gov (T.F. Osborne).

<https://doi.org/10.1016/j.jor.2020.03.045>

Received 12 March 2020; Accepted 25 March 2020

Available online 01 April 2020

0972-978X/ Published by Elsevier B.V. on behalf of Professor P K Surendran Memorial Education Foundation.

and revision arthroplasties. These complications increase hospital length of stay (LOS) and rates of readmission, and thereby have profound medical and financial ramifications for patients and hospital systems. The economic burden on the U.S. healthcare system is enormous, with an average revision THA costing \$77,000 and costs compounding with each additional day of hospitalization.^{6,7}

1.2. Rationale

The Affordable Care Act (ACA) was signed into law in 2010 to expand coverage and realign the US healthcare system.⁸ Section 3205 of the ACA established the Hospital Readmission Reduction Program (HRRP), which incentivizes institutions to improve quality of care by aligning reimbursements with outcome. More specifically, the HRRP utilizes hospital-specific, risk-standardized all-cause 30-day readmission rates as a measure of hospital performance. Underperforming hospitals are penalized by a reduction in Medicare reimbursements for inpatient services.⁹ Due to these stipulations, it behooves healthcare providers to reduce readmission rates by improving perioperative care transitions and overall patient care. One of the first areas in the field of orthopedics to be affected by these ACA policies was total joint arthroplasty (TJA).⁸ Focusing on readmission rate reduction is especially appealing because Medicare covers roughly two thirds of THAs in the U.S., making it the largest single payer for hip arthroplasties.¹⁰ Moreover, readmissions related to surgical complications are far more expensive than those related to medical complications, with an average cost of \$27,979 for surgical complications as compared to \$11,682 for medical complications.¹¹ With these fiscal and health considerations, many research teams have proposed statistical models predicting readmission after THA. It is imperative that these models are broadly compared and reconciled in order to maximize clinical usability.

1.3. Questions

- (1) Are there validated statistical models that predict 30-day readmissions for THA patients when appraised with a standards-based, reliable assessment tool?
- (2) Which evidence-based factors are significant and have support across the models for predicting risk of 30-day readmissions post-THA?

2. Material and methods

2.1. Search strategy and criteria

This study followed criteria set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) statement.¹² The paper heading, use of the PRISMA flow diagram shown in Table 1 for study selection,¹³ and use of the PRISMA-P checklist in Electronic Supplementary Material 1 reflect adherence to the PRISMA-P criteria.¹⁴ In addition, a-priori protocol registration and description were done at the PROSPERO registry site (Registration number: CRD42018108571).¹⁵

The initial search was begun with manual exploration of printed articles in the hospital medical library as well as electronically searched articles on Google Scholar. Important and relevant reference articles from the initial search were additionally obtained, accounting for 28 papers during manual search. Analysis of these papers helped establish an automated strategy for searching electronic databases. This systematic review describes readmission prediction models for hip arthroplasty alone; however, the search criteria was formulated for both hip and knee arthroplasty procedures. This strategy was adopted for completeness since our initial search revealed that some studies had used combined hip and knee cohorts for building models. A medical librarian and one author (BA & SM) designed and implemented all the searches in the following databases: (1) PubMed; (2) Embase; (3) Ovid

MEDLINE; (4) Cochrane Database of Systematic Reviews; (5) Web of Science. If the database did not take the exact date for search, it was approximated to the nearest month and/or year. We searched for papers between the date of inception of each database and April 2019. Across databases, the search was begun with hospital readmission as the exploded Medical Subject Headings (MeSH) term and the key words *readmi**, *rehosp**, where * was used as the truncation character. Second, we searched for risk as the exploded MeSH term and the key words *model**, *predict**, *use**, *util**, and *risk**. Third, we performed a search that used the exploded MeSH term *arthroplasty*, *replacement*, *total*, *partial*, *prosthesis*, and *knee*. Fourth, we performed a search that used the exploded MeSH term *arthroplasty*, *replacement*, *total*, *partial*, *hemi-arthroplasty*, *prosthesis*, and *hip*. Lastly, we combined all the search criteria that identified our final reference set in each database.

2.2. Inclusion and exclusion

Studies were considered eligible if they (a) used readmission as an independent or composite outcome; (b) measured readmission after index hospitalization for THA; (c) examined the association between readmission and predictors using multivariate statistical model; (d) were published in the English language.

2.3. Assessment of study quality


Table 1 shows the steps of article selection in the PRISMA flow diagram. It also shows exclusion criteria at each step of the selection process, starting with 2933 articles and ending with 358 articles for full review.

In the final step, we excluded studies (n = 83) that (1) analyzed readmissions after generic index admission and did not have THA as the discharge diagnosis; (2) created cohorts based on explicit subgroups such as revision arthroplasty, partial- or hemi-arthroplasties, and hip fracture. Each paper selected for the detailed review was appraised for risk of bias using the Transparent Reporting of a multivariate prediction model for Individual Prognosis Or Diagnosis (TRIPOD) quality assessment tool.¹⁶ The TRIPOD standard is designed for transparent reporting of studies developing, validating, or updating a multivariate prediction model for prognostic purposes. It is implemented as a 22-item checklist (Electronic Supplementary Material 2) that provides comprehensive criteria for assessing the quality and thoroughness of the reporting provided in predictive modeling studies. Electronic Supplementary Material 3 shows the checklist applied to all the models in the final selection of studies. The TRIPOD tool factored out studies that did not analyze multivariate models (n = 213) and, thus, it reduced the risk of bias in the final selection of studies. During this step, we also found other reviews (n = 10); five of these were related to the postoperative management and interventions after THA discharge and hence were excluded from our analysis. The remaining five studies are noted in the Results section.

2.4. Data collection and abstraction

Our detailed review entailed 26 studies that described 28 risk models (7 combined hip and knee arthroplasty cohort models and 21 THA models). This analysis was carried out by at least two authors separately (AM & SM; CN & SM; JB & SM), and results of the selection process were verified for selection bias and resolution of low-confidence selections by each author. A predictive model was considered to be a statistical construct for this review, created to understand the combined effect of predictors derived from known data sources on readmission as an outcome, using a specific study design. In addition, we extracted the following data items from each study in a tabulated format in three separate documents: (1) research study design, country where study was conducted, data source and timeframe of data cohort, derivation and validation cohort sizes, statistical model used, whether risk score

Table 1
PRISMA 2009 Flow Diagram for THA.¹³



was created (items summarized as research study characteristics and shown in Table 2); (2) readmission as a single or composite outcome measure, whether outcome was THA-specific or all-cause or surrogate readmission measure, timeframe used for readmission, observed readmission rate, and C-statistics or Area Under Curve (AUC) for validation cohort (items summarized as outcome characteristics and shown in Table 3); (3) significant risk factors in each final model (items summarized as risk factors characteristics and shown in Table 4).

3. Results

We found five reviews during our final article selection process that met our initial inclusion criteria: Hofstede et al. (2016) did a systematic review following the PRISMA guidelines that analyzed one-year follow-up and independent factors for patients with osteoarthritis on radiological confirmation in prospective studies. The study, however, focused on only patient related factors and found low quality of evidence across the studies.¹⁷ Two reviews focused on total joint arthroplasties and did not adhere to formal systematic review standards; they are literature reviews and described modifiable and non-modifiable risk factors for patients undergoing joint arthroplasties.^{18,19} One of the two studies (Sveom et al. (2017)) also considered perioperative risk factors including administrative and systemic factors after the discharge and hence did not describe predictive factors for readmissions.¹⁹ Podmore et al. (2018) considered short- and long-term impacts of comorbidities in joint arthroplasty patients on many outcome variables, including readmission²⁰; risk factors other than comorbidities were not

considered in the review. Thus, none of the reviews has aimed to carry out a systematic review adhering to the specific standards of reporting to understand quantitative impact of the risk factors on readmission post-THA.

To date, we found one validated statistical model that predicts 30-day readmission for THA patients, and one validated model that includes a combined THA and TKA cohort: Siracuse et al. (2016) created and validated a THA model that explained 89.1% variability in readmission in their cohort analysis, with a derivation cohort of 268,518 and a validation cohort of 153,560 patients for the years 2006–2011. Thirty-day readmission rates were 5.89% and 5.82% for the derivation and validation cohorts, respectively. This model is encouraging in terms of applicability to clinical practice, given its large cohort size and validation. However, while the reported R^2 of 89.1% explains a great degree of variance in the outcome measure, AUC was not reported. AUC reporting is broadly preferred over R^2 reporting, given that AUC measures discriminative capability. The second validated model from Mesko et al. (2014) had a retrospective cohort of 1291 combined THA and TKA patients from 2010 to 2011. Their model exhibited an AUC of 0.76 for the validation cohort, with internal validation done via bootstrapping using 1000 samples. This model is encouraging in terms of reporting and discriminative capability, though validation on an external cohort is preferred as compared to internal validation, given that linear models often suffer from difficulties generalizing to new populations. These two models confirm that there do indeed exist validated statistical models for predicting 30-day readmissions after THA. Nonetheless, these models are an extreme minority of the 28 total

Table 2
Study design characteristics for studies for readmissions for THA.

Study	Research Study Design	Data Source	Year(s) of Data	Procedures Per Derivation Cohort	Procedures Per Validation Cohort	Statistical Model	Country/Risk Score Creation
(Higuera, Elsharkawy et al., 2011)-a (THA subgroup)	Prospective	Single center EHR system	2008	198 THA	NR	HMLR	USA/No
(Khan, Hossain et al., 2012)	Retrospective	Single center EHR system	2009–2010	467 THA	NR	MLR	UK/No
(Clement, Derman et al., 2013)	Retrospective	Single center EHR system	2009–2011	1583 THA	NR	MLR	USA/No
(Pugely, Callaghan et al., 2013)-a (THA subgroup)	Retrospective	ACS NSQIP	2011	8105 THA	NR	MLR	USA/No
(Mednick, Alvi et al., 2014)	Retrospective	ACS NSQIP	2011	9441 THA	NR	MLR	USA/No
(Schairer, Sing et al., 2014)	Retrospective	Single center EHR system	2005–2011	1415 THA	NR	CPHR	USA/No
(Basques, Bohl et al., 2015)	Retrospective	ACS NSQIP	2011–2012	8434 THA	NR	MLR	USA/No
(Heyes, Tucker et al., 2015)	Retrospective	Single center EHR system	2010–2012	424 THA	NR	MLR	UK/No
(Stavrakis, SooHoo et al., 2015)	Retrospective	OSHPD	1995–2010	202986 THA	NR	MLR	USA/No
(Martin, Gao et al., 2016)	Retrospective	ACS NSQIP	2012–2013	15163 THA	NR	MLR	USA/No
(Siracuse and Chamberlain 2016)	Retrospective	HCUP for 4 states	2006–2011	268518 THA	153560 THA	MLR	USA/Yes
(Weiss, Garellick et al., 2016)	Retrospective	Swedish hip arthroplasty register	1992–2012	6690 THA	NR	CPHR	Sweden/No
(Ali, Loeffler et al., 2017)	Retrospective	NHS ES	2006–2016	514455 THA	NR	MLR	UK/No
(Shah, Keswani et al., 2017)	Retrospective	ACS NSQIP	2011–2014	3120 THA	NR	MLR	USA/No
(Sofu, Üçpınar et al., 2017)	Retrospective	Single center EHR system	2010–2014	517 THA	NR	MLR	Turkey/No
(Cantrell, DeBell et al., 2018)	Retrospective	ACS NSQIP	2005–2015	10032 THA	NR	MLR	US/No
(Kimball, Nichols et al., 2018)-a (THA subgroup)	Retrospective	CMS files	2014–2015	26837 THA	NR	CPHR	USA/No
(White, Sastow et al., 2018)-a (30-day readmissions)	Retrospective	SID (California, Florida, and New York) & HCUP	2007–2011	274851 THA	NR	MLR	USA/No
(White, Sastow et al., 2018)-b (90-day readmissions)	Retrospective	SID (California, Florida, and New York) & HCUP	2007–2011	274851	NR	MLR	USA/No
(Zmistowski, Restrepo et al., 2013)	Retrospective	Single center EHR system	2004–2008	5426 THA	NR	MLR	USA/No
(Mesko, Bachmann et al., 2014)	Retrospective	Single center EHR system	2010–2011	1291 THKA combined	1291 (with bootstrapping of 1000 samples)	MLR	USA/Yes
(Tiberi, Hansen et al., 2014) (Only for cirrhosis patients undergoing THKA)	Retrospective – 1:2 matched case control	Single center EHR system	2000–2012	230 THKA combined	NR	MLR	USA/Yes
(Ricciardi, Oi et al., 2017)	Retrospective – 1:2 matched case control	Single center EHR system	2010–2014	21864 THKA combined	NR	MLR	USA/No
(Sher, Keswani et al., 2017)	Retrospective	ACS NSQIP	2011–2014	7474 THKA combined	NR	MLR	USA/No
(Yao, Keswani et al., 2017)-a (THA subgroup)	Retrospective	ACS NSQIP	2011–2014	50376 THA	NR	MLR	USA/No
(Schroer, Diesfeld et al., 2018)	Retrospective	Multi center (5) EHR system	2014–2015	6968 THKA combined	NR	DS	USA/No
(Swenson, Bastian et al., 2018)-a (30-day readmissions)	Retrospective	Single center EHR system	2013–2015	622 THKA combined	NR	MLR	USA/No
(Swenson, Bastian et al., 2018)-b (90-day readmissions)	Retrospective	Single center EHR system	2013–2015	622 THKA combined	NR	MLR	USA/No

ACS NSQIP: American College of Surgeons National Surgical Quality Improvement Program; CMS: Center for Medicare and Medicaid Services; CPHR: Cox Proportional Hazards Regression; DS: Descriptive Statistics; EHR: Electronic Health Record; HCUP: Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality; HMLR: Hierarchical Logistic Regression Model using Generalized Estimating Equations; MLR: Multivariate Logistic Regression; NHS ES: National Health Service Hospital Episode Statistics database; NR: Not Reported; OSHPD: California Office of Statewide Health Planning and Development; SID: State Inpatient Database; THA: Total Hip Arthroplasty; THKA: Total Hip or Knee Arthroplasty.

Table 3
Outcome characteristics for studies for readmissions for THA.

Study	Outcome: Readmission - Single Measure or Composite (Readmission, Mortality, Complications Requiring Readmission)	Readmission type: All-or-any Cause or Other	Readmission Days	Observed Readmission Rate (%)	C-statistics or AUC for Validation Cohort
(Higuera, Elsharkawy et al., 2011)-a (THA subgroup)	Composite – complications	All	90	9.4	NR
(Khan, Hossain et al., 2012)	Single	All	28	11.8	NR
(Clement, Derman et al., 2013)	Single	All	30	6.5	NR
(Pugely, Callaghan et al., 2013)-a (THA subgroup)	Composite – complications	All	30	4.2	NR
(Mednick, Alvi et al., 2014)	Single	All	30	3.7	0.737
(Schairer, Sing et al., 2014)	Composite – complications	All	30 and 90	4.0 and 8.0	NR
(Basques, Bohl et al., 2015)	Single	All	30	10.0	NR
(Heyes, Tucker et al., 2015)	Single	All	365	21.0	NR
(Stavrakis, SooHoo et al., 2015)	Composite – complications	All	30	3.9	NR
(Martin, Gao et al., 2016)	Single	All	30	8.5	NR
(Siracuse and Chamberlain 2016)	Single	All	30	5.9	NR
(Weiss, Garellick et al., 2016)	Composite – readmission, mortality	Other –cardiovascular	90	30.2	NR
(Ali, Loeffler et al., 2017)	Single	All	30	5.9	NR
(Shah, Keswani et al., 2017)	Single	All	30	9.8	NR
(Softu, Upunur et al., 2017)	Single	All	30	12.2	NR
(Cantrell, DeBell et al., 2018)	Single	All	30	8.5	NR
(Kimball, Nichols et al., 2018)-a (THA subgroup)	Single	All	30	6.7	NR
(White, Sastow et al., 2018)-a (30-day readmissions)	Single	All	30	5.6	0.681
(White, Sastow et al., 2018)-b (90-day readmissions)	Single	All	90	10.2	0.660
(Zmistowski, Restrepo et al., 2013)	Composite – complications	All	30 and 90	3.1 and 5.3	NR
(Mesko, Bachmann et al., 2014)	Single	All	30	3.6	0.760
(Tiberi, Hansen et al., 2014) (Only for cirrhosis patients undergoing THKA)	Composite – complications	All	90	10.0	NR
(Ricciardi, Oi et al., 2017)	Single	All	30	0.3	NR
(Sher, Keswani et al., 2017)	Composite – complications	All	30	1.9	NR
(Yao, Keswani et al., 2017)-a (THA subgroup)	Composite – complications	All	30	3.1	NR
(Schroer, Diesfield et al., 2018)	Composite – complications	All	90	8.4	NR
(Swenson, Bastian et al., 2018)-a (30-day readmissions)	Single	All	90	3.4	NR
(Swenson, Bastian et al., 2018)-b (90-day readmissions)	Single	All	90	5.7	NR

AUC: Area Under Curve; NR: Not Reported; THA: Total Hip Arthroplasty.

Table 4
Risk factor characteristics for studies for readmissions for THA.

Predictors (level)	Unit of measure & comparison	Effect Size [CI] (wrt reference) ^{a,b}	Study
Demographics			
Age (patient)	70-79/≥90 years	OR: 1.35 [1.09–1.67] (≥90 wrt 70-79)	(Basques, Bohl et al., 2015)
Age (patient)	≤55/56-65/66-75/≥76 years	OR: 2.02 [1.14–3.60] (≥76 wrt ≤55)	(Clement, Derman et al., 2013)
Age (patient)	65-74/75-84/85+ years	RR: 1.45 [1.08–1.94] (75-84 wrt 65-74)	(Higuera, Elsharkawy et al., 2011)-a
Age (patient)	65-74/75-84/85+ years	RR: 1.79 [1.08–2.10] (85+ wrt 65-74)	(Higuera, Elsharkawy et al., 2011)-b
Age (patient)	65-74/75-84/85+ years	RR: 1.43 [1.14–1.80] (75-84 wrt 65-74)	(Higuera, Elsharkawy et al., 2011)-b
Age (patient)	65-74/75-84/85+ years	RR: 1.25 [0.79–1.98] (85+ wrt 65-74)	(Higuera, Elsharkawy et al., 2011)-b
Age (patient)	Continuous years	OR: 1.06 [1.02–1.06]	(Khan, Hossain et al., 2012)
Age (patient)	< 45/46-55/56-65/66-75/76-85/ > 85 years	OR: 2.59 [1.44–4.67] (< 45 wrt 56-65)	(Pugely, Callaghan et al., 2013)-b
Age (patient)	50-59/60-69/70-79/ > 80	OR: 1.79 [1.09–2.97] (> 85 wrt 56-65)	(Sher, Keswani et al., 2017)
Age (patient)	50-59/60-69/70-79/ > 80	OR: 1.40 [0.72–2.69] (50-59 wrt < 50)	(Sher, Keswani et al., 2017)
Age (patient)	50-59/60-69/70-79/ > 80	OR: 1.66 [0.87–3.16] (60-69 wrt < 50)	(Sher, Keswani et al., 2017)
Age (patient)	50-59/60-69/70-79/ > 80	OR: 2.33 [1.18–4.59] (70-79 wrt < 50)	(Sher, Keswani et al., 2017)
Age (patient)	50-59/60-69/70-79/ > 80	OR: 4.17 [1.18–4.59] (> 80 wrt < 50)	(Sher, Keswani et al., 2017)
Age (patient)	21-30/31-40/41-50/51-60/61-70/71-80/81-90/ > 90 years	OR: 1.46 [1.17–1.82] (21-30 wrt 41-50)	(Siracuse and Chamberlain 2016)
Age (patient)	21-30/31-40/41-50/51-60/61-70/71-80/81-90/ > 90 years	OR: 0.99 [0.85–1.15] (31-40 wrt 41-50)	(Siracuse and Chamberlain 2016)
Age (patient)	21-30/31-40/41-50/51-60/61-70/71-80/81-90/ > 90 years	OR: 0.91 [0.84–0.98] (51-60 wrt 41-50)	(Siracuse and Chamberlain 2016)
Age (patient)	21-30/31-40/41-50/51-60/61-70/71-80/81-90/ > 90 years	OR: 0.98 [0.91–1.06] (61-70 wrt 41-50)	(Siracuse and Chamberlain 2016)
Age (patient)	21-30/31-40/41-50/51-60/61-70/71-80/81-90/ > 90 years	OR: 1.37 [1.28–1.47] (71-80 wrt 41-50)	(Siracuse and Chamberlain 2016)
Age (patient)	21-30/31-40/41-50/51-60/61-70/71-80/81-90/ > 90 years	OR: 1.97 [1.82–2.13] (81-90 wrt 41-50)	(Siracuse and Chamberlain 2016)
Age (patient)	21-30/31-40/41-50/51-60/61-70/71-80/81-90/ > 90 years	OR: 2.22 [1.87–2.63] (> 90 wrt 41-50)	(Siracuse and Chamberlain 2016)
Age (patient)	Continuous years	OR: 1.11 [1.07–1.14]	(Sofu, Üçpunar et al., 2017)
Age (patient)	< 60/60-75/ > 75 years	HR: 4.2 (60-75 wrt < 60) HR: 10.6 (> 75 wrt < 60)	(Weiss, Garellick et al., 2016)
Age (patient)	Continuous years	OR: 1.56 [1.27–1.92]	(Yao, Keswani et al., 2016)-a
BMI - obesity (patient)	< 30/ > = 30 kg/m ²	OR: 1.15 [1.09–1.21] (≥30 wrt < 30)	(Siracuse and Chamberlain 2016)
BMI (patient)	< 18/18-25/25-30/30-35/≥35 kg/m ²	OR: 1.73 [1.24–2.44] (≥35 wrt 18-25)	(Basques, Bohl et al., 2015)
BMI (patient)	< 25/25- < 30/30- < 35/ > = 35 kg/m ²	OR: 2.28 [1.27–4.09] (≥35 wrt < 25)	(Clement, Derman et al., 2013)
BMI (patient)	< 18.5/25- < 30/30- < 35/35-40/ > 40 kg/m ²	OR: 1.94 [1.02–3.70] (≥40 wrt < 18.5)	(Mednick, Alvi et al., 2014)
BMI (patient)	< 35/ > 35 kg/m ²	OR: 1.47 [1.11–1.97] (> 35 wrt < 35)	(Pugely, Callaghan et al., 2013)-a
BMI (patient)	< 40/ > 40 kg/m ²	OR: 2.11 [1.19–3.72] (> 40 wrt < 40)	(Shah, Keswani et al., 2017)
BMI (patient)	BMI > 40 kg/m ²	OR: 1.25 [0.73–2.16] (BMI > 40 wrt no)	(Sher, Keswani et al., 2017)
BMI (patient)	BMI > 40 kg/m ²	OR: 1.47 [1.23–1.74] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
BMI (patient)	Obesity as BMI > 45 kg/m ² (% readmitted)	11.3%	(Schroer, Diesfield et al., 2018)
Race (patient)	African/White	OR: 0.66 [0.48–0.91] (White wrt African)	(Zmistowski, Restrepo et al., 2013)
Race (patient)	White/African/Hispanic-Asian-Native (Other)	OR: 1.23 [1.15–1.31] (African wrt White)	(Siracuse and Chamberlain 2016)
Race (patient)	White/African/Hispanic-Asian-Native (Other)	OR: 1.02 [0.97–1.08] (Other wrt White)	(Siracuse and Chamberlain 2016)
Race (patient)	White/African/Hispanic-Asian-Native	OR: 1.48 [1.34–1.62] (African wrt White)	(Stavrakis, SooHoo et al., 2015)
Race (patient)	White/African/Hispanic-Asian-Native	OR: 0.79 [0.67–0.93] (Asian wrt White)	(Stavrakis, SooHoo et al., 2015)
Race (patient)	Latino/non-Latino	OR: 5.78 [4.04–7.52] (Latino wrt non-Latino)	(Swenson, Bastian et al., 2018)-a
Race (patient)	Latino/non-Latino	OR: 9.09 [7.16–11.02] (Latino wrt non-Latino)	(Swenson, Bastian et al., 2018)-b
Sex (patient)	Male/Female	OR: 1.36 [1.05–1.75] (Male wrt Female)	(Zmistowski, Restrepo et al., 2013)
Sex (patient)	Male/Female	OR: 1.40 [1.20–1.63] (Male wrt Female)	(Basques, Bohl et al., 2015)
Sex (patient)	Male/Female	OR: 1.25 [1.03–1.53] (Male wrt Female)	(Pugely, Callaghan et al., 2013)-b
Sex (patient)	Male/Female	OR: 0.96 [0.93–0.99] (Female wrt Male)	(Siracuse and Chamberlain 2016)
Sex (patient)	Male/Female	OR: 2.78 [1.76–3.80] (Female wrt Male)	(Swenson, Bastian et al., 2018)-b
Administrative			
Admission source (system)	Home/Non-home	OR: 2.36 [1.19–4.66] (Non-home wrt Home)	(Khan, Hossain et al., 2012)
Disposition (system)	Home/IRF	OR: 1.99 [1.50–2.64] (IRF wrt Home)	(Zmistowski, Restrepo et al., 2013)
Disposition (system)	Home/Non-home facility	OR: 1.42 [1.08–1.86] (Non-home facility wrt Home)	(Basques, Bohl et al., 2015)
Disposition (system)	Home/SNF/ALF	OR: 1.71 [0.35–0.98] (Non-home wrt Home)	(Heyes, Tucker et al., 2015)
Disposition (system)	Other location (than home): Yes/No	OR: 7.72 [5.87–9.57] (Yes wrt No)	(Swenson, Bastian et al., 2018)-a
Disposition (system)	Other location (than home): Yes/No	OR: 8.90 [6.74–11.06] (Yes wrt No)	(Swenson, Bastian et al., 2018)-b
Distance to facility (patient)	Continuous kilometers	OR: 0.52 [0.40–0.66]	(Zmistowski, Restrepo et al., 2013)
Income (patient)	First/Second/Third/Fourth quartile	OR: 1.18 [1.12–1.24] (First wrt Fourth)	(Siracuse and Chamberlain 2016)
Income (patient)	First/Second/Third/Fourth quartile	OR: 1.07 [1.02–1.12] (Second wrt Fourth)	(Siracuse and Chamberlain 2016)
Income (patient)	First/Second/Third/Fourth quartile	OR: 1.03 [0.99–1.08] (Third wrt Fourth)	(Siracuse and Chamberlain 2016)
Insurance (patient)	Private/Medicare/Medicaid/Other	OR: 1.21 [1.15–1.27] (Medicare wrt Private) OR: 1.68 [1.47–1.92] (Medicaid wrt Private) OR: 1.26 [1.04–1.54] (Other wrt Private)	(Stavrakis, SooHoo et al., 2015)
LOS (patient)	Continuous days	OR: 10.71 [5.68–20.19]	(Zmistowski, Restrepo et al., 2013)
LOS (patient)	Continuous days	OR: 1.09 [1.03–1.16]	(Clement, Derman et al., 2013)
LOS (patient)	Continuous days	OR: 0.95 [0.88–1.02]	(Mednick, Alvi et al., 2014)
LOS (patient)	≤5/ > 5 days	HR: 3.26 [2.1–5.1] (> 5 wrt ≤ 5)	(Schairer, Sing et al., 2014)
LOS (patient)	< 7/ > = 7 days	OR: 3.13 [0.12–0.62] (≥7 wrt < 7)	(Heyes, Tucker et al., 2015)
Preoperative stay > 24 h (patient)	Yes/No	OR: 1.45 [0.77–2.71] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Time to surgery (system)	< 36 h/ > 36 h	OR: 1.62 [0.16–2.45] (> 36 wrt < 36)	(Heyes, Tucker et al., 2015)

(continued on next page)

Table 4 (continued)

Predictors (level)	Unit of measure & comparison	Effect Size [CI] (wrt reference) ^{a,b}	Study
Type of anesthesia (provider)	Spinal/Other	RR: 0.65 [0.51–0.81] (Spinal wrt Other)	(Higuera, Elsharkawy et al., 2011)-b
Type of surgery (patient)	THA/TKA	OR: 2.64 [1.84–3.44] (THA wrt TKA)	(Swenson, Bastian et al., 2018)-a
Type of surgery (patient)	THA/TKA	OR: 3.04 [2.14–3.94] (THA wrt TKA)	(Swenson, Bastian et al., 2018)-b
Type of surgery - revision (provider)	Primary/Revision/AS THA	HR: 1.84 [1.2–2.9] (Revision wrt Primary)	(Schairer, Sing et al., 2014)
Type of surgery - revision (provider)	Primary/Revision THA	HR: 1.85 [1.0–3.5] (AS wrt Primary)	(Siracuse and Chamberlain 2016)
Type of surgery - use of specific prosthesis (provider)	DHS/CN/HA THA	OR: 1.82 [1.75–1.90] (Revision wrt Primary)	(Siracuse and Chamberlain 2016)
Type of surgery - procedure (provider)	IMN/HA/ORIF/Total THA	OR: 1.51 [0.41–1.08] (CN wrt DHS)	(Heyes, Tucker et al., 2015)
		OR: 3.10 [0.19–1.80] (HA or THA wrt DHS)	
		OR: 1.3 [1.1–1.5] (HA wrt IMN)	(Martin, Gao et al., 2016)
		OR: 1.2 [1.1–1.4] (ORIF wrt IMN)	
		OR: 1.4 [1.1–1.9] (Total wrt IMN)	
Clinical			
Fracture etiology (patient)	Yes/No	OR: 1.71 [1.25–2.34] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
Hemoglobin level drop (patient)	< 2/ ≥ 2 g/dL	OR: 1.29 [0.49–1.25]	(Heyes, Tucker et al., 2015)
MELD score = 10 x [(0.957 x Ln serum creatinine) + (0.378 x Ln serum total bilirubin) + (1.12 Ln INR) + 0.643] (patient)	Continuous	OR: 2.99 [1.28–7.00]	(Tiberi, Hansen et al., 2014)
Preoperative serum albumin level (patient)	Continuous g/dL	OR: 0.69 [0.48–0.99]	(Mednick, Alvi et al., 2014)
Transfusion status (patient)	≥ 2 units: Yes/No	OR: 1.85 [0.49–7.05] (Yes wrt No)	(Heyes, Tucker et al., 2015)
Comorbidities			
Alcohol abuse (patient)	None/Alcoholic	OR: 1.52 [0.26–1.67] (Alcoholic wrt None)	(Heyes, Tucker et al., 2015)
Anemia (patient)	Hemoglobin < 10 g/dL (% readmitted)	20%	(Schroer, Diesfield et al., 2018)
Anemia (patient)	HCT ≤ 36/ > 36: Yes/No	OR: 1.2 [1.1–1.4] (Yes wrt No)	(Martin, Gao et al., 2016)
Anemia (patient)	Yes/No	OR: 1.19 [1.15–1.25] (Yes wrt No)	(Siracuse and Chamberlain 2016)
Arrhythmia (patient)	Yes/No	OR: 1.47 [1.36–1.60] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Arthritis (patient)	Yes/No	OR: 1.22 [1.09–1.36] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
ASA class (patient)	Class 1 or 2/Class 3 or 4	OR: 1.42 [1.01–2.00] (ASA class 3 or 4 wrt ASA class 1 or 2)	(Sher, Keswani et al., 2017)
ASA class (patient)	Class 3 or 4	OR: 1.69 [1.50–1.89] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
ASA class (patient)	Class4/Class 3/Class 1-2	OR: 1.95 [1.48–2.57] (3 wrt 1-2)	(Pugely, Callaghan et al., 2013)-a
		OR: 2.74 [1.48–5.08] (4 wrt 1-2)	
ASA class (patient)	Class 3/Class 4/Class 1-2	OR: 1.40 [1.09–1.79] (3 wrt 1-2)	(Basques, Bohl et al., 2015)
		OR: 1.90 [1.41–2.51] (4 wrt 1-2)	
ASA class (patient)	1/2/3/4	OR: 3.68 [0.06–1.15] (2 wrt 1)	(Heyes, Tucker et al., 2015)
		OR: 1.95 [0.18–1.48] (3 wrt 1)	
		OR: 2.14 [0.16–1.34] (4 wrt 1)	
ASA class (patient)	Class 3/Class4/Class 1-2	OR: 1.5 [1.2–1.7] (3 wrt 1-2)	(Martin, Gao et al., 2016)
		OR: 1.7 [1.4–2.1] (4 wrt 1-2)	
ASA class (patient)	Class 3-4/not 3-4	OR: 1.71 [1.19–2.46] (3-4 wrt not 3-4)	(Shah, Keswani et al., 2017)
ASA class (patient)	Class 3-4/not 3-4	OR: 2.85 [1.47–5.52] (3-4 wrt not 3-4)	(Sofu, Üçpunar et al., 2017)
Atherosclerosis (patient)	Yes/No	OR: 1.31 [1.18–1.45] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Avascular necrosis etiology (patient)	Relative to osteoarthritis or other etiology: Yes/No	OR: 1.55 [1.25–1.92] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
Bleeding disorder (patient)	Yes/No	OR: 1.76 [1.38–2.26] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
Bleeding disorder (patient)	Yes/No	OR: 2.10 [1.32–3.37] (Yes wrt No)	(Pugely, Callaghan et al., 2013)-a
Bleeding disorder (patient)	Yes/No	OR: 1.51 [0.75–3.03] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Bleeding disorder (patient)	Yes/No	OR: 1.3 [1.1–1.5] (Yes wrt No)	(Martin, Gao et al., 2016)
Bleeding disorder (patient)	Yes/No	OR: 1.19 [1.08–1.32] (Yes wrt No)	(Siracuse and Chamberlain 2016)
Bleeding disorders (patient)	Current bleeding-causing disorder: Yes/No	OR: 2.56 [1.22–5.38] (Yes wrt No)	(Sher, Keswani et al., 2017)
Cancer - disseminated (patient)	Yes/No	OR: 1.5 [1.1–2.0] (Yes wrt No)	(Martin, Gao et al., 2016)
Cancer - disseminated (patient)	Yes/No	OR: 1.93 [1.01–3.68] (Yes wrt No)	(Shah, Keswani et al., 2017)
Cancer (patient)	Yes/No	OR: 1.26 [1.05–1.51] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Cardiac disease (patient)	Chronic heart failure in 30 days prior to surgery, myocardial infarction within 6 months of surgery, previous percutaneous coronary intervention, or history of angina within 1 month of surgery (yes/no)	OR: 1.44 [0.73–2.84] (Yes wrt No)	(Sher, Keswani et al., 2017)
Cardiac valve disease (patient)	Yes/No	HR: 2.5 [1.3–5.1] (Yes wrt No)	(Schairer, Sing et al., 2014)
CCI (patient)	Index between 0 and 8	RR: 1.17 [1.07–1.28] (Per index point increase)	(Higuera, Elsharkawy et al., 2011)-a
CCI (patient)	Index between 0 and 8	RR: 1.18 [1.11–1.26] (Per index point increase)	(Higuera, Elsharkawy et al., 2011)-b
CCI (patient)	0/2/ > 2	HR: 3.4 (> 2 wrt 0)	(Weiss, Garellick et al., 2016)
Chronic heart failure (patient)	Yes/No	OR: 2.41 [1.30–4.49] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
Congestive heart failure (patient)	Yes/No	RR: 2.93 [1.07–8.05] (Yes wrt No)	(Higuera, Elsharkawy et al., 2011)-a
Congestive heart failure (patient)	Yes/No	OR: 1.54 [1.39–1.71] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Congestive heart failure (patient)	Yes/No	OR: 1.49 [1.38–1.61] (Yes wrt No)	(Siracuse and Chamberlain 2016)
COPD (patient)	Yes/No	OR: 1.36 [0.76–2.44] (Yes wrt No)	(Mednick, Alvi et al., 2014)
COPD (patient)	Yes/No	OR: 1.45 [1.34–1.56] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
COPD (patient)	Yes/No	OR: 1.3 [1.1–1.5] (Yes wrt No)	(Martin, Gao et al., 2016)

(continued on next page)

Table 4 (continued)

Predictors (level)	Unit of measure & comparison	Effect Size [CI] (wrt reference) ^{a,b}	Study
COPD (patient)	Yes/No	OR: 1.33 [1.27–1.39] (Yes wrt No)	(Siracuse and Chamberlain 2016)
Decubitus ulcer (patient)	Yes/No	OR: 1.61 [1.18–2.20] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Depression (patient)	Yes/No	OR: 3.48 [1.43–8.51] (Yes wrt No)	(Ricciardi, Oi et al., 2017)
Diabetes - uncomplicated (patient)	Yes/No	OR: 1.21 [1.16–1.27] (Yes wrt No)	(Siracuse and Chamberlain 2016)
Diabetes - with complications (patient)	Yes/No	HR: 11.55 [3.6–36.8] (Yes wrt No)	(Schairer, Sing et al., 2014)
Diabetes (patient)	Yes/No	OR: 1.28 [0.82–2.01] (Yes wrt No)	(Sher, Keswani et al., 2017)
Diabetes (patient)	Uncontrolled status > 180 mg/dL blood glucose (% readmitted)	11%	(Schroer, Diesfield et al., 2018)
Diabetes (patient)	Yes/No	OR: 1.21 [1.04–1.40] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
Diabetes (patient)	Yes/No	OR: 3.34 [1.54–7.25] (Yes wrt No)	(Khan, Hossain et al., 2012)
Diabetes (patient)	Yes/No	OR: 1.24 [0.75–2.06] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Diabetes (patient)	Yes/No	OR: 1.28 [1.19–1.38] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Diabetes (patient)	Yes/No	OR: 1.37 [0.98–1.93] (Yes wrt No)	(Shah, Keswani et al., 2017)
Dyspnea (patient)	Yes/No	OR: 1.3 [1.1–1.6] (Yes wrt No)	(Martin, Gao et al., 2016)
Fluid & electrolyte disorders (patient)	Yes/No	OR: 1.21 [1.14–1.27] (Yes wrt No)	(Siracuse and Chamberlain 2016)
Functional status (patient)	Dependency: Yes/No	OR: 1.47 [1.08–2.01] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
Functional status (patient)	Dependent/Independent	OR: 1.78 [1.09–2.90] (Dependent wrt Independent)	(Pugely, Callaghan et al., 2013)-a
Functional status (patient)	Dependent/Partially Dependent/Independent	OR: 1.31 [1.11–1.54] (Partially Dependent wrt Independent) OR: 1.41 [1.01–1.97] (Dependent wrt Independent)	(Basques, Bohl et al., 2015)
Functional status (patient)	Dependent/Independent	OR: 1.66 [1.10–2.50] (Dependent wrt Independent)	(Shah, Keswani et al., 2017)
Hematological disease (patient)	Yes/No	OR: 2.64 [1.88–3.73] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Hypertension (patient)	Yes/No	OR: 1.28 [0.91–1.79] (Yes wrt No)	(Sher, Keswani et al., 2017)
Hypertension (patient)	Yes/No	OR: 23.6 [22.4–24.8] (Yes wrt No)	(Swensen, Bastian et al., 2018)-b
Hypertension (patient)	Yes/No	OR: 1.22 [1.09–1.36] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
Hypertension (patient)	Yes/No	OR: 1.26 [0.88–1.82] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Hypertension (patient)	Yes/No	OR: 1.21 [1.02–1.45] (Yes wrt No)	(Basques, Bohl et al., 2015)
Hypertension (patient)	Yes/No	OR: 1.2 [1.1–1.4] (Yes wrt No)	(Martin, Gao et al., 2016)
Hypertension (patient)	Yes/No	OR: 1.17 [1.12–1.21] (Yes wrt No)	(Siracuse and Chamberlain 2016)
Ischemic heart disease/arrhythmia (patient)	Yes/No	RR: 1.60 [1.20–1.40] (Yes wrt No)	(Higuera, Elsharkawy et al., 2011)-a
Ischemic heart disease/arrhythmia (patient)	Yes/No	RR: 1.73 [1.36–2.21] (Yes wrt No)	(Higuera, Elsharkawy et al., 2011)-b
Ischemic heart disease/arrhythmia (patient)	Yes/No	OR: 1.84 [1.00–3.40] (Yes wrt No)	(Sofu, Üçpunar et al., 2017)
Liver disease (patient)	Yes/No	OR: 1.57 [1.39–1.77] (Yes wrt No)	(Siracuse and Chamberlain 2016)
Lymphoma (patient)	Yes/No	OR: 23.6 [22.25–24.95] (Yes wrt No)	(Swensen, Bastian et al., 2018)-b
Malnutrition (patient)	Albumin < 3.4 g/dL (% readmitted)	8.8%	(Schroer, Diesfield et al., 2018)
Narcotic use (patient)	Narcotic prescription filled within 3 months of surgery (% readmitted)	10.7%	(Schroer, Diesfield et al., 2018)
Neurological disorder (patient)	History: Yes/No	OR: 5.66 [2.79–11.47] (Yes wrt No)	(Khan, Hossain et al., 2012)
Number of comorbidities (patient)	Continuous	OR: 1.53 [1.17–1.90]	(Swenson, Bastian et al., 2018)-a
Pneumonia (patient)	Yes/No	OR: 1.52 [1.08–2.12] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Preoperative corticosteroid use (patient)	Yes/No	OR: 1.64 [1.03–2.61] (Yes wrt No)	(Pugely, Callaghan et al., 2013)-a
Preoperative corticosteroid use (patient)	Yes/No	OR: 2.93 [1.73–4.95] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Preoperative corticosteroid use (patient)	Yes/No	OR: 1.38 [1.04–1.83] (Yes wrt No)	(Basques, Bohl et al., 2015)
Preoperative corticosteroid use (patient)	Yes/No	OR: 1.86 [1.21–2.89] (Yes wrt No)	(Shah, Keswani et al., 2017)
Prior cardiac surgery (patient)	Yes/No	OR: 1.92 [0.71–5.22] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Protein deficiency (patient)	Yes/No	OR: 1.99 [1.49–2.64] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Psychiatric disease (patient)	Yes/No	OR: 1.97 [1.65–2.35] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Pulmonary disease (patient)	Yes/No	OR: 8.83 [7.20–10.47] (Yes wrt No)	(Swenson, Bastian et al., 2018)-b
Pulmonary disease (patient)	Yes/No	OR: 1.36 [0.65–2.86] (Yes wrt No)	(Sher, Keswani et al., 2017)
Pulmonary disease (patient)	Yes/No	OR: 1.45 [1.17–1.80] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
Pulmonary Disease (patient)	Yes/No	OR: 1.46 [1.22–1.75] (Yes wrt No)	(Basques, Bohl et al., 2015)
Renal disease (patient)	Yes/No	OR: 1.57 [1.39–1.76] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Renal failure - end stage disease (patient)	Yes/No	OR: 2.64 [1.81–3.85] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Renal failure (patient)	Yes/No (Creatinine > 1.2/≤1.2)	OR: 1.2 [1.1–1.4] (Yes wrt No)	(Martin, Gao et al., 2016)
Renal failure (patient)	Yes/No	OR: 1.26 [1.18–1.36] (Yes wrt No)	(Siracuse and Chamberlain 2016)
Rheumatoid arthritis (patient)	Yes/No	OR: 1.19 [1.10–1.29] (Yes wrt No)	(Siracuse and Chamberlain 2016)
Severe adverse event pre-discharge (patient)	Yes/No	OR: 1.76 [1.11–2.78] (Yes wrt No)	(Yao, Keswani et al., 2016)-a

(continued on next page)

Table 4 (continued)

Predictors (level)	Unit of measure & comparison	Effect Size [CI] (wrt reference) ^{a,b}	Study
Severe pre-discharge adverse event (patient)	Wound infection, thromboembolic event, myocardial infarction, wound dehiscence, unplanned intubation, ventilator > 48 h, renal insufficiency, renal failure, stroke/CVA, cardiac arrest requiring CPR, sepsis, septic shock, death: Yes/No	OR: 13.13 [5.1–33.79] (Yes wrt No)	(Sher, Keswani et al., 2017)
Smoking (patient)	Tobacco use: Yes/No (% readmitted)	7.6%	(Schroer, Diesfield et al., 2018)
Smoking (patient)	Yes/No	OR: 1.62 [1.06–2.46] (Yes wrt No)	(Sher, Keswani et al., 2017)
Smoking (patient)	Yes/No	OR: 1.38 [1.20–1.58] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
Smoking (patient)	None/Ex-smoker/Smoker	OR: 1.14 [0.64–2.00] (Ex-smoker wrt None)	(Heyes, Tucker et al., 2015)
		OR: 1.24 [0.56–2.73] (Smoker wrt None)	
Steroids (patient)	Yes/No	OR: 1.79 [0.86–3.74] (Yes wrt No)	(Sher, Keswani et al., 2017)
Steroids for chronic disease (patient)	Yes/No	OR: 1.43 [1.14–1.79] (Yes wrt No)	(Yao, Keswani et al., 2016)-a
Stroke (patient)	Yes/No	3 OR: .75 [2.66–5.28] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Substance abuse (patient)	Yes/No	HR: 2.05 [0.9–4.8] (Yes wrt No)	(Schairer, Sing et al., 2014)
Vascular disease (patient)	Yes/No	OR: 1.48 [1.31–1.67] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Postoperative surgical complications			
Deep venous thrombosis (patient)	Yes/No	OR: 14.37 [5.39–38.29] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Infection (patient)	Yes/No	OR: 1.59 [1.05–2.38] (Yes wrt No)	(Stavrakis, SooHoo et al., 2015)
Pulmonary embolism (patient)	Yes/No	OR: 19.09 [5.82–62.65] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Superficial surgical site infection (patient)	Yes/No	OR: 29.66 [14.43–60.96] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Postoperative medical complications			
Number of significant risk factors (patient)	0/1/2/3/≥4	OR: 1.22 [0.95–1.57] (1 wrt 0) p > 0.05 OR: 1.90 [1.51–2.40] (2 wrt 0) OR: 3.20 [2.54–4.02] (3 wrt 0) OR: 5.06 [4.01–6.38] (≥4 wrt 0)	(Yao, Keswani et al., 2016)-a
Pneumonia (patient)	Yes/No	OR: 2.72 [0.67–11.05] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Postoperative ICU stay (system)	Yes/No	OR: 2.09 [1.12–3.88]	(Sofu, Üçpunar et al., 2017)
Sepsis or septic shock (patient)	Yes/No	OR: 9.85 [3.39–28.64] (Yes wrt No)	(Mednick, Alvi et al., 2014)
Urinary tract infection (patient)	Yes/No	OR: 2.18 [0.90–5.31] (Yes wrt No)	(Mednick, Alvi et al., 2014)

a: Effect size reported as Adjusted Odds Ratio (OR) or Hazards Ratio (HR) or Relative Risks Ratio (RR) typically at $p < 0.05$ (some ratios significant at higher p values reported by some authors); b: Odds ratio for continuous variables is reported as change in readmission odds for unit change in continuous variable; wrt: with respect to; ALF: Assisted Living Facility; AS: Antibiotic Spacer; ASA: American Society of Anesthesiologists patient fitness level before surgery; BMI: Body Mass Index; CCI: Charlson Comorbidity Index; CI: Confidence Interval; CN: Cephalomedullary Nail; COPD: Chronic Obstructive Pulmonary Disease; DHS: Dynamic Hip Screw; HA: Hemiarthroplasty; HCT: Hematocrit; HHC: Home Health Care; ICU: Intensive Care Unit; IMN: Intra-Medullary Nail; IRF: Inpatient Rehabilitation Facility; LOS: Length of Stay; MELD: Model for End-stage Liver Disease; ORIF: Open Reduction Internal Fixation; QOL: Quality of Life; SNF: Skilled Nursing Facility; TKA: Total Knee Arthroplasty; THA: Total Hip Arthroplasty.

models studied, suggesting room for improvement in terms of model construction and validation.

3.1. Study characteristics

We examined 28 models in our final selection that proposed significant, contributory factors to 30-day readmissions. From a demographic standpoint, age was the leading risk factor for 30-day readmissions, followed by BMI, gender, and race (Fig. 1). From an administrative perspective, disposition, LOS, and type of surgery were the leading risk factors for readmission (Fig. 2). From a clinical standpoint, anemia and transfusion status were the leading risk factors (Fig. 3). In terms of comorbidities contributing to increased readmission rates, ASA class, hypertension, preoperative corticosteroid use, and presence of a bleeding disorder were most cited (Fig. 4). In terms of postoperative complications, severe adverse event pre-discharge, DVT, infection, pneumonia, postoperative ICU stay, pulmonary embolism, sepsis, superficial surgical site infection, and urinary tract infection were referenced once each as risk factors.

There is high heterogeneity in this study analysis. For example, seven models noted hypertension as a significant predictor of 30-day THA readmission. However, these models do not uniformly delineate the duration or severity of a patient's hypertension, such as if patients are categorized into elevated blood pressure, stage 1 hypertension, or stage 2 hypertension, or when their blood pressure was measured.²¹ The presence of heterogeneity thus makes it difficult to perform pooled regression—otherwise known as meta-analysis—of effect sizes for

various significant risk factors. We therefore analyzed risk factors highlighted as significant by multiple studies. Consensus around significant risk factors provides valuable information regarding directions for future modeling efforts as well as clinical and care practice take-aways.

3.2. TRIPOD analysis

TRIPOD is a global, consensus-based quality assessment tool that defines a gold standard for reporting of predictive models. Examples of specific items to be included in reporting are description of sample size, outcome, limitations, and explanation of statistical models.²² While the TRIPOD standard was published in 2015, prior precedent standards such as the CHARMS checklist²³ and CASP tool²⁴ were widely available before then, and none of the studies published before 2015 in our review used those standards for reporting and quality assessment.

4. Discussion

Specific outcome measurements, such as hospital readmissions following surgery, have shown that the increasing demand for aging-related procedures has led to greater expenses for patients and hospitals alike. The majority of primary THA procedures are covered by Medicare, with patients in the age range of 65–84 years.²⁵ Recent changes in payment structure, with a focus on value-based care, have incentivized both patients and healthcare providers to identify risks and improve transition of care and care continuum processes that lead to

reductions in readmissions. Therefore, accurate risk assessment tools can have a dramatic impact on both medical and surgical costs and outcomes. This study therefore investigates statistical models that predict 30-day readmission rates for THA patients, evaluates their reporting of performance measures and predictivity statistics using standard TRIPOD criteria, and identifies significant predictors for readmission following primary THA.

4.1. Data synthesis across studies

All the models were published in the last decade from 2011 to 2018, and the majority of them (23 out of 28, or 82%) were built in the USA.^{26–46} Three models were built in the UK^{47–49} and one each in Sweden⁵⁰ and Turkey.⁵¹ One model was based on a prospective design,³⁰ and the remaining (96%) were retrospective designs, with two models applying additional case control.^{37,43} While the creation and implementation of a prospective study design is more difficult than that of a retrospective design, it is greatly preferred: prospective modeling or validation ensures that models are robust to changes in the underlying population over time, thereby allaying concerns about the generalizability of multivariate linear models. For example, the past 15 years have seen a rise in accelerated rehabilitation, the role of orthogeriatricians, and changes to anticoagulation medications. Prospective designs serve to incorporate such changes over time by leveraging developed models in practice and measuring the concurrence between model predictions and clinical outcomes on a case-by-case basis. In turn, these prospectively validated models are significantly more applicable to ongoing policy decisions.

In our review, most studies used either the Electronic Health Records (EHR) database at the facility (13 out of 28, or 46%) or the American College of Surgeons – National Surgical Quality Improvement Program (ACS NSQIP) database (8 out of 28, or 29%) for building models. The other data sources used were: insurance files, health databases, and surgical procedure registers at a national level (3 out of 28, or 11%), and health databases at a state level (4 out of 28, or 14%). The models were built with a minimum of 230 patients to a maximum of 514,455 patients.

4.2. Study reporting

The majority of the studies in our review lacked in-depth descriptions of the models when measured against standard TRIPOD criteria. Four out of 26 studies reported a C-statistic or AUC as a measure of model performance. Heterogeneity or absence of reporting of performance measure renders comparison efforts to assess predictive quality of the models difficult, especially given that some measures describe goodness-of-fit (for example, R^2) while others describe discriminatory capability (for example, AUC). Further, it should be noted that the TRIPOD standard was published in 2015 – therefore, it is likely that several of the studies included in this review did not have access to the checklist at the time of analysis. Indeed, the TRIPOD standard was itself designed to combat poor model reporting practices for prediction models. However, certain aspects of the TRIPOD standard were widely accepted before its publication, particularly by standard tools such as the CHARMS checklist (2014) and CASP tool (2006). For example, model discriminatory performance reporting was requested as early as the 2006 version of the CASP tool. Authors of predictive modeling studies should be mindful to check their reporting against whatever prevalent reporting standards exist at the time of publication.

Empirical readmission rates showed a large variance, ranging from 0.3% to 30.2%, with three studies not even reporting the base rate. Such wide variation might be attributable to a multitude of cohort-related factors and facility-specific interventions, procedures, and protocols.

Two of 26 studies used validation cohorts. This practice, requiring to keep 10%–30% of the cohort data aside to measure the performance




Fig. 1. Demographic risk factors and their support from studies for readmissions post-THA.

of the models built using the remaining 70%–90% of the data, is relatively easy to implement but was not adopted by the majority of the studies in our review. This scarcity of validated studies impedes deployment of models in clinical setting.

4.3. Significant risk factors

We identified significant factors correlated to post-THA readmissions along with the number of studies supporting each factor as shown in Figs. 1–4.

Diabetes has been discussed extensively as a risk factor for THA readmissions amongst various reviews.^{18–20,52} Age is another risk factor indicated both in our analysis as well as in prior literature. Specifically, Hofstede et al. (2016) identified patients over the age of 60 to be at risk of readmission following THA,¹⁷ while Sveom et al. (2017) specified that patients over the age of 80 are especially at risk.¹⁹ Iorio et al. (2017) cited anemia as a risk factor for THA readmissions.⁵² Siddiqi et al. (2017) identified pre-existing renal insufficiency as a risk factor for readmission due to postoperative acute renal failure.⁵³ Sveom et al. (2017), in addition to corroborating diabetes and age as risk factors, also cited COPD and LOS as risk factors for readmission.¹⁹ Podmore et al. (2018) provided support for hypertension and lung disease as risk factors for readmission.²⁰ Among predictors referenced by at least six studies,^{32,33,36,40,41,45} one of which was a study with a validation cohort, coagulopathy or bleeding disorder had not been referenced in earlier studies.

American Society of Anesthesiologists Physical Status (ASA) class was referenced as a risk factor for readmission by eight different studies.^{26,32,36,39,40,45,48,51} All eight studies found that ASA class 3 or 4 was a significant risk factor for readmission when compared to ASA class 1 or 2. ASA classes 3 and 4 respectively represent patients with severe systemic disease and with constant threat to life and thus signify higher risk for readmission. While it is likely that surgeons already inform their sickest patients about the risks of surgery and offer help to control chronic medical conditions before opting for THA, it is critical that the entire care team, including anesthesiologists and postoperative nursing teams, are aware of the patient's ASA status and corresponding risks.

Preoperative corticosteroid use was also referenced as a risk factor for readmission by four different studies when compared to no corticosteroid use.^{26,33,36,39} Corticosteroids act as immunosuppressive agents by decreasing transcription of pro-inflammatory markers. Therefore, use of preoperative corticosteroids dampens the body's ability to mount a robust immune response, leading to an increased probability of surgical site and wound infections given surgical manipulation.^{54,55} Furthermore, chronic use of corticosteroids predisposes




Fig. 2. Administrative risk factors and their support from studies for readmissions post-THA.

patients to endocrine pathologies such as Cushing's syndrome, which have been shown to negatively affect the wound healing process by inhibiting proliferation of fibroblasts and leading to increased rates of infection given decreased lymphocyte counts and chronically elevated cortisol levels.⁵⁶ Given the agreement across multiple studies of the significance of preoperative corticosteroid use as a predictive risk factor for post-THA readmission, surgical teams should coordinate with the primary care team to taper corticosteroid use preoperatively.

Discharge disposition was referenced as a risk factor for readmission by four different studies.^{26,46,48,57} Overall, a discharge to home elicited the best outcomes when compared to other options, such as an inpatient rehabilitation facility and skilled nursing facility. Discharge to a non-home facility likely implies an overall lower health status, impaired functional status, or lack of social support, which may be independent or interrelated risk factors for increased risk of readmission. This

system-level risk factor also puts an additional burden on care transition.

Functional status was referenced as a risk factor for readmission by four different studies,^{26,36,39,45} all of which found that a dependent or partially dependent functional status was a risk factor for readmission when compared to an independent functional status. These degrees of functional status are measured by a patient's ability to independently perform activities of daily living (ADLs). A multitude of parameters could render a patient dependent or partially dependent, such as intense pain, infection, structural abnormalities, comorbidities, frailty, lack of adequate post-operative rehabilitation, or severe obesity. The inability to independently perform ADLs has been shown to increase morbidity and mortality after general, vascular, and orthopedic surgeries such as THA.⁵⁸ This compromised ability to perform ADLs leads to an increased sedentary state, thereby increasing the risk of deep vein




Fig. 3. Clinical risk factors and their support from studies for readmissions post-THA.




Fig. 4. Comorbidities and their support from studies for readmissions post-THA.

thrombosis, atelectasis, and pneumonia, especially in elderly populations – all of which increase the risk of 30-day readmission.^{59,60} Lack of autonomous mobility given decreased baseline functional activity can also increase likelihood of physical deconditioning, which may in turn lead to increased risk of readmission via falling or other adverse events.^{61,62} Functional status is not a risk factor that can be easily resolved preoperatively; however, early perioperative physical therapy may improve patients' physical status and mobility, making them more robust to postoperative risks.

In summary, the limited evidence from the two validated models and corroboration of the risk factors from other studies suggests that researchers have been able to build predictive models for assessing the risk of readmission post-THA with modest predictive capability.

4.4. Limitations

Despite adhering to rigorous process and applying multi-author voting for the article selection process, there is a possibility of selection bias in our review. We might have missed some studies written in non-English languages without known available translations. Since we focused on primary THA cohort studies in our review, some additional nuances related to revision arthroplasties and hip fracture cohorts are missing in our analyses. Since all but one of the studies in our review were retrospective observational cohorts, there is inherent systemic bias in their results, despite the evidence for many motivating predictors. Our review is also limited by the poor adherence to the standard TRIPOD development and reporting criteria and lack of use of procedures such as testing the models with external validation cohorts.

5. Conclusions

Our review of predictive models for the risk of readmission post-THA entailed 28 models from the detailed analyses of 26 studies using the TRIPOD quality assessment criteria. Most models were built within the last eight years in the U.S., either using a facility EHR system or the ACS NSQIP database. Despite two validated models showing predictive capabilities, most studies lacked novel methods for building the models

and reporting of performance measurements. These findings suggest that there is ample opportunity for increased rigor and consistency in model reporting. Bleeding disorder, ASA class 3 or 4, preoperative corticosteroid use, and non-home discharge disposition were found to be risk factors of significance for post-THA readmission. Future predictive modeling studies ought to focus on including these significant risk factors to maximize predictivity, and on adhering to standard, TRIPOD-based model reporting and validation practices. These endeavors will increase clinical usability and facilitate meta-analysis of models across studies.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jor.2020.03.045>.

References

- Knickman JR, Snell EK. The 2030 problem: caring for aging baby boomers. *Health Serv Res.* 2002;37(4):849–884.
- Yoon RS, Mahure SA, Hutzler LH, Iorio R, Bosco JA. Hip arthroplasty for fracture vs elective care. One bundle does not fit all. *J Arthroplasty.* 2017;32(8):2353–2358.
- Kremers HM, Larson DR, Crowson CS, et al. Prevalence of total hip and knee replacement in the United States. *J Bone Jt Surg Am Vol.* 2015;97(17):1386.
- Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. *J Bone Jt Surg Am Vol.* 2007;89(4):780–785.
- Hutzler L, Williams J. Decreasing the incidence of surgical site infections following joint replacement surgery. *Bull Hosp Jt Dis.* 2017;75(4):268–273.
- Gwam CU, Mistry JB, Mohamed NS, et al. Current epidemiology of revision total hip arthroplasty in the United States: national Inpatient Sample 2009 to 2013. *J Arthroplasty.* 2017;32(7):2088–2092.
- Mahure SA, Hutzler L, Yoon RS, Bosco JA. Economic impact of nonmodifiable risk factors in orthopaedic fracture care: is bundled payment feasible? *J Orthop Trauma.* 2017;31(3):175–179.
- Chambers MC, Ei-Othmani MM, Saleh KJ. Health care reform impact on total joint replacement. *Orthop Clin N Am.* 2016;47(4):645–+.

9. Kocher RP, Adashi EY. Hospital readmissions and the Affordable Care Act: paying for coordinated quality care. *Jama*. 2011;306(16):1794–1795.
10. Ong KL, Mowat FS, Chan N, Lau E, Halpern MT, Kurtz SM. Economic burden of revision hip and knee arthroplasty in Medicare enrollees. *Clin Orthop Relat Res*. 2006;446:22–28.
11. Clair AJ, Evangelista PJ, Lajam CM, Slover JD, Bosco JA, Iorio R. Cost analysis of total joint arthroplasty readmissions in a bundled payment care improvement initiative. *J Arthroplasty*. 2016;31(9):1862–1865.
12. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4(1):1–9.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097 1–6.
14. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015;350 g7647.
15. Dissemination CfRa. PROSPERO: *International Prospective Register of Systematic Reviews*. NHS: National Institute for Health Research; 2019 Published 2011 <https://www.crd.york.ac.uk/prospero/>, Accessed date: 26 June 2019.
16. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med*. 2015;162(1):W1–W73.
17. Hofstede SN, Gademan MG, Vliet Vlieland TP, Nelissen RG, Marang-van de Mheen PJ. Preoperative predictors for outcomes after total hip replacement in patients with osteoarthritis: a systematic review. *BMC Musculoskel Disord*. 2016;17:212.
18. Romero JA, Jones RE, Brown T. Modifiable risk factors and preoperative optimization of the primary total arthroplasty patient. *Curr Orthop Pract*. 2017;28(3):272–275.
19. Sveom DS, Otteman MK, Garvin KL. Improving quality and decreasing cost by reducing Re-admissions in patients undergoing total joint arthroplasty. *Curr Rev Musculoskel Med*. 2017;10(3):388–396.
20. Podmore B, Hutchings A, van der Meulen J, Aggarwal A, Konan S. Impact of comorbid conditions on outcomes of hip and knee replacement surgery: a systematic review and meta-analysis. *BMJ Open*. 2018;8(7):e021784.
21. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2018;71(19):e127–e248.
22. Collins G, Reitsma J, Altman D, Moons K. Members of Tg. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *Eur Urol*. 2015;67(6):1142–1151.
23. Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. *PLoS Med*. 2014;11(10):e1001744.
24. CASP E. *Critical appraisal skills programme clinical prediction rule checklist*. 2006;2006:1–6 https://casp-uk.net/wp-content/uploads/2018/01/CASP-Clinical-Prediction-Rule-Checklist_2018.pdf.
25. Kim S. Changes in surgical loads and economic burden of hip and knee replacements in the US: 1997–2004. *Arthritis Rheum*. 2008;59(4):481–488.
26. Basques BA, Bohl DD, Golinvaux NS, Leslie MP, Baumgaertner MR, Grauer JN. Postoperative length of stay and 30-day readmission after geriatric hip fracture: an analysis of 8434 patients. *J Orthop Trauma*. 2015;29(3):e115–120.
27. Cantrell CK, DeBell HA, Lehtonen EJ, et al. Risk factors for readmission within thirty days following revision total hip arthroplasty. *J Clin Orthop Trauma*. 2018;11(1):38–42.
28. Clement RC, Derman PB, Graham DS, et al. Risk factors, causes, and the economic implications of unplanned readmissions following total hip arthroplasty. *J Arthroplasty*. 2013;28(8 Suppl):7–10.
29. French DD, Bass E, Bradham DD, Campbell RR, Rubenstein LZ. Rehospitalization after hip fracture: predictors and prognosis from a national veterans study. *J Am Geriatr Soc*. 2008;56(4):705–710.
30. Higuera CA, Elsharkawy K, Klika AK, Brocone M, Barsoum WK. 2010 Mid-America Orthopaedic Association Physician in Training Award: predictors of early adverse outcomes after knee and hip arthroplasty in geriatric patients. *Clin Orthop Relat Res*. 2011;469(5):1391–1400.
31. Kimball CC, Nichols CI, Nunley RM, Vose JG, Stambough JB. Skilled nursing facility star rating, patient outcomes, and readmission risk after total joint arthroplasty. *J Arthroplasty*. 2018;33(10):3130–3137.
32. Martin CT, Gao Y, Pugely AJ. Incidence and risk factors for 30-day readmissions after hip fracture surgery. *Iowa Orthop J*. 2016;36:155–160.
33. Mednick RE, Alvi HM, Krishnan V, Lovecchio F, Manning DW. Factors affecting readmission rates following primary total hip arthroplasty. *J Bone Jt Surg Am Vol*. 2014;96(14):1201–1209.
34. Mesko NW, Bachmann KR, Kovacevic D, LoGrasso ME, O'Rourke C, Froimson MI. Thirty-day readmission following total hip and knee arthroplasty - a preliminary single institution predictive model. *J Arthroplasty*. 2014;29(8):1532–1538.
35. Molina CS, Thakore RV, Blumer A, Obrensky WT, Sethi MK. Use of the national surgical quality improvement Program in orthopaedic surgery. *Clin Orthop Relat Res*. 2015;473(5):1574–1581.
36. Pugely AJ, Callaghan JJ, Martin CT, Cram P, Gao Y. Incidence of and risk factors for 30-day readmission following elective primary total joint arthroplasty: analysis from the ACS-NSQIP. *J Arthroplasty*. 2013;28(9):1499–1504.
37. Ricciardi BF, Oi KK, Daines SB, Lee YY, Joseph AD, Westrich GH. Patient and perioperative variables affecting 30-day readmission for surgical complications after hip and knee arthroplasties: a matched cohort study. *J Arthroplasty*. 2017;32(4):1074–1079.
38. Schairer WW, Sing DC, Vail TP, Bozic KJ. Causes and frequency of unplanned hospital readmission after total hip arthroplasty. *Clin Orthop Relat Res*. 2014;472(2):464–470.
39. Shah CK, Keswani A, Chi D, Sher A, Koenig KM, Moucha CS. Nonelective primary total hip arthroplasty: the effect of discharge destination on postdischarge outcomes. *J Arthroplasty*. 2017;32(8):2363–2369.
40. Sher A, Keswani A, Yao DH, Anderson M, Koenig K, Moucha CS. Predictors of same-day discharge in primary total joint arthroplasty patients and risk factors for post-discharge complications. *J Arthroplasty*. 2017;32(9):S150–+.
41. Siracuse BL, Chamberlain RS. A preoperative scale for determining surgical readmission risk after total hip replacement. *JAMA Surg*. 2016;151(8):701–709.
42. Stavrakis AI, SooHoo NF, Lieberman JR. Bilateral total hip arthroplasty has similar complication rates to unilateral total hip arthroplasty. *J Arthroplasty*. 2015;30(7):1211–1214.
43. Tiberi 3rd JV, Hansen V, El-Abbadi N, Bedair H. Increased complication rates after hip and knee arthroplasty in patients with cirrhosis of the liver. *Clin Orthop*. 2014;472(9):2774–2778.
44. White RS, Sastow DL, Gaber-Baylis LK, Tangel V, Fisher AD, Turnbull ZA. Readmission rates and diagnoses following total hip replacement in relation to insurance payer status, race and ethnicity, and income status. *J Racial Ethn Health Disparities*. 2018;5(6):1202–1214.
45. Yao DH, Keswani A, Shah CK, Sher A, Koenig KM, Moucha CS. Home discharge after primary elective total joint arthroplasty: postdischarge complication timing and risk factor Analysis. *J Arthroplasty*. 2017;32(2):375–380.
46. Zmistowski B, Restrepo C, Hess J, Adibi D, Cangoz S, Parvizi J. Unplanned readmission after total joint arthroplasty: rates, reasons, and risk factors. *J Bone Jt Surg Am Vol*. 2013;95(20):1869–1876.
47. Ali AM, Loeffler MD, Aylin P, Bottle A. Factors associated with 30-day readmission after primary total hip arthroplasty analysis of 514 455 procedures in the UK national health service. *Jama Surg*. 2017;152(12).
48. Heyes GJ, Tucker A, Marley D, Foster A. Predictors for readmission up to 1 Year following hip fracture. *Arch Plus*. 2015;4(2):e27123.
49. Khan MA, Hossain FS, Dashti Z, Muthukumar N. Causes and predictors of early readmission after surgery for a fracture of the hip. *J Bone Joint Surg*. 2012;94(5):690–697.
50. Weiss RJ, Garellick G, Kärrholm J, Hailer NP. Total hip arthroplasty in 6690 patients with inflammatory arthritis: effect of medical comorbidities and age on early mortality. *J Rheumatol*. 2016;43(7):1320–1327.
51. Sofu H, Üçpınar H, Çamurcu Y, et al. Predictive factors for early hospital readmission and 1-year mortality in elder patients following surgical treatment of a hip fracture. *Ulusal Travma ve Acil Cerrahi Dergisi*. 2017;23(3):245–250.
52. Iorio R, Osmani FA. Strategies to prevent periprosthetic joint infection after total knee arthroplasty and lessen the risk of readmission for the patient. *J Am Acad Orthop Surg*. 2017;25:S13–S16.
53. Siddiqi A, White PB, Etcheson JI, et al. Acute kidney injury after total knee arthroplasty: a clinical review. *Surg Technol Int*. 2017;31:243–252.
54. Boddapati V, Fu M, Su E, Sculco P, Bini S, Mayman D. Preoperative corticosteroid use for medical conditions is associated with increased postoperative infectious complications and readmissions after total hip arthroplasty: a propensity-matched study. *Am J Orthoped*. 2018;47(12).
55. Durant S, Duval D, Homo-Delarche F. Factors involved in the control of fibroblast proliferation by glucocorticoids: a review. *Endocr Rev*. 1986;7(3):254–269.
56. Aubert C, Folly A, Mancinetti M, Hayoz D, Donzé J. Association of stress biomarkers with 30-day unplanned readmission and death. *J Hosp Med*. 2017;12(7):523–529.
57. Swenson ER, Bastian ND, Nembhard HB, Davis CM. Reducing cost drivers in total joint arthroplasty: understanding patient readmission risk and supply cost. *Health Syst*. 2018;7(2):135–147.
58. Scarborough JE, Bennett KM, Englum BR, Pappas TN, Lago-Deenadayalan SA. The impact of functional dependency on outcomes after complex general and vascular surgery. *Ann Surg*. 2015;261(3):432.
59. Hatipoğlu U, Wells BJ, Chagin K, Joshi D, Milinovich A, Rothberg MB. Predicting 30-day all-cause readmission risk for subjects admitted with pneumonia at the point of care. *Respir Care*. 2018;63(1):43–49.
60. Woodfield JC, Jamil W, Sagar PM. Incidence and significance of postoperative complications occurring between discharge and 30 days: a prospective cohort study. *J Surg Res*. 2016;206(1):77–82.
61. Slyepchenko A, Maes M, Jacka FN, et al. Gut microbiota, bacterial translocation, and interactions with diet: pathophysiological links between major depressive disorder and non-communicable medical comorbidities. *Psychother Psychosom*. 2017;86(1):31–46.
62. Britteon P, Cullum N, Sutton M. Association between psychological health and wound complications after surgery. *Br J Surg*. 2017;104(6):769–776.